Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Cancer Therapies Should Be Held To Higher Bar In Maintenance Setting, ODAC Says

Mar 26 2012

• By Sue Sutter

Related Content

Will Maintenance Sell In NSCLC? Experts Weigh Costs Against Benefits

Sep 13 2010

Merck, GSK Sarcoma Drugs Bring Different Efficacy Stories To FDA Panel Review

Mar 16 2012

Related Companies

Merck & Co., Inc.

Genentech, Inc.

OSI Systems, Inc.

Eli Lilly and Company

ARIAD Pharmaceuticals, Inc.

GSK plc

Additional Topics

Advisory Committees Drug Approval Standards BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window